Clinical Trial Update: Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab in pediatric and adult patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, assessing response in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING